Curcumin for Type 2 Diabetic Patients
Study Details
Study Description
Brief Summary
There are evidence that there is an association between insulin resistance and prolonged hyperinsulinemia or hyperglycemia in Type 2 diabetic patients. This will trigger oxidative stress system via reactive oxygen species (ROS) and lead to a high level of Nitric oxide. This can contribute to a significant change in blood vessel and could end up with the complications from cardiovascular disease and increased mortality rate of type 2 diabetic patients. The purpose of the present study was to examine the effectiveness of the curcumin in type 2 diabetic patients on the reduction of atherosclerosis events by examining pulse-wave velocity (PWV) and plasma high-sensitivity C-reactive protein (CRP) test and on blood sugar lowering, glycosylated hemoglobin (HBA1c), lipid profile, and insulin resistance.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
Phase 4 |
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Placebo Comparator: Placebo
|
Drug: curcumin
Curcumin capsule contains 250 mg curcuminoids, 2 capsule per time, 3 times a day for 12 months
Other Names:
|
Experimental: Curcumin
|
Drug: curcumin
Curcumin capsule contains 250 mg curcuminoids, 2 capsule per time, 3 times a day for 12 months
Other Names:
|
Outcome Measures
Primary Outcome Measures
- to determine the effectiveness of curcumin on reduction of atherosclerotic events and risks in Type 2 diabetic patients [12 months]
Secondary Outcome Measures
- To examine the effectiveness of curcumin on the reduction of blood sugar, glycosylated hemoglobin (HBA1c), lipid profile, and insulin resistance [12 months]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Diabetic patients aged 35 years or older and did not use insulin during the first 5 years of treatment after being diagnosed (with or without symptoms listed in the following inclusion criteria)
-
Patient with hyperlipidemia (Cholesterol ≥ 200 mg/dl, TG ≥ 150 mg/dl, LDL ≥ 100 mg/dl and HDL ≥ 35 mg/dl)
-
Patient with hypertension (Blood pressure ≥ 130/85 mmHg or take hypertensive drugs)
-
Obesity (BMI ≥ 25)
Exclusion Criteria:
-
Current diagnosis of secondary peripheral arterial disease (PAD) (except listed in the inclusion criteria item 1-4)
-
Current diagnosis of cardiovascular disease, i.e., coronary arterial disease and cerebrovascular disease
-
Current diagnosis of end stage renal function with serum creatinine > 2.0 mg/dl or on renal dialysis
-
Current diagnosis of cirrhosis with ALT ≥ 3 times of normal range
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | HRH Princess Maha Chakri Sirindhorn Medical Center | Ongkarak | Nakornnayok | Thailand | 26120 |
Sponsors and Collaborators
- Srinakharinwirot University
- Ministry of Health, Thailand
Investigators
- Principal Investigator: Somlak Chuengsamarn, Medical Doctor, Srinakarinwirot University
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- SWUEC30/2550